Georgia is a Vice President in the DDF team having joined SV as an Associate in 2023. Georgia represents the fund on the board of NRG Therapeutics, and serves on the boards of Trimtech Therapeutics, Leal Therapeutics, LoQus23 Therapeutics, and Cerevance as a Board Observer.
Before joining SV, Georgia was a life sciences consultant at EmPartners, advising on strategy across the product life cycle and assessing competitive threats to preclinical through Phase III assets. Before joining EmPartners, Georgia was a Postdoctoral Fellow in Dr Yueming Li's lab at the Sloan Kettering Institute, where she investigated the interplay between inflammation and amyloid beta in Alzheimer’s disease. Georgia received a PhD in Neuroscience from Weill Cornell Medicine and has published in high impact journals (Nature, PNAS, Neuron, and Science Translational Medicine).
In her free time, Georgia enjoys playing and watching football, travelling, and scuba diving.
Academic Credentials
Georgia received a PhD in Neuroscience from Weill Cornell Medicine, and a BSc in Neuroscience (with a minor in Economics) from Allegheny College.




